Therapies directed at Janus kinase in different autoimmune rheumatic diseases: a mechanism-based approach

Abstract

Introduction: Janus kinase (JAK)-targeted therapy has become a promising approach in the treatment of some autoimmune rheumatological pathologies, including A.R, ankylosing spondylitis, psoriatic arthritis, etc. Objective: To evaluate the role of Janus kinase therapies in the treatment of autoimmune rheumatological diseases and to understand the mechanism of action of these therapies. Methodology: A collection of information from scientific journals was used, using library research tools, databases and search engines.  Results: Janus kinase-targeted therapies have been shown to be safe and effective in the treatment of rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus and vasculitis. Monitoring of patients during treatment is recommended. Conclusion: Clinical studies have demonstrated that these drugs are safe and effective in these diseases and show promising results in other autoimmune diseases as well. However, further research is essential to determine long-term efficacy and safety.